AOD 9604 had six human trials and 900 participants. Phase IIa showed positive results. Then the pivotal Phase IIb failed at every dose tested. Development was terminated in 2007. The trial history is Retatrutide & AOD9604: A Deep Dive into the "Triple Plus" Protocol We know that Retatrutide is the new heavy hitter on the block, but when you add AOD9604 to the mix, you aren't Chevy Chase AOD 9604 Anti Obesity Peptide for Fat Loss Important Update on FDA Changes Concerning Peptides